Company news

MetaVia Inc. news in 2024

MetaVia Inc.'s news releases, calls and decks from 2024, newest first.

View company

MetaVia to Participate in the 9th Annual MASH-TAG 2025 Conference After Releasing Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH

December 18, 2024

MetaVia Announces Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH

December 17, 2024

MetaVia to Present at the Emerging Growth Conference in December

December 1, 2024

NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic Diseases

November 17, 2024

NeuroBo Pharmaceuticals to Participate in Investor Conferences in November

November 12, 2024

NeuroBo Pharmaceuticals to Present at the November 21st Virtual Investor Summit Microcap Event

November 10, 2024

NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

November 6, 2024

NeuroBo Pharmaceuticals to Participate in Investor Conferences in October

September 30, 2024

NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

September 29, 2024

NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

September 2, 2024

NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update

August 13, 2024

NeuroBo Pharmaceuticals Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity

August 5, 2024

NeuroBo Pharmaceuticals Announces Exclusive License Agreement with MThera Pharma for NB-01

July 29, 2024

NeuroBo Pharmaceuticals to Present at the Emerging Growth Conference in July

July 10, 2024

NeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

June 25, 2024

NeuroBo Pharmaceuticals Announces up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

June 23, 2024

NeuroBo Pharmaceuticals' DA-1241 in Combination with Semaglutide Improves Liver Fibrosis and Demonstrates Additive Hepatoprotective Effects in Pre-Clinical MASH Models Compared to Either Treatment, Alone

May 21, 2024

NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 8, 2024

NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in June

April 29, 2024

NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

April 16, 2024

NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

March 31, 2024

NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update

March 27, 2024

NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer

March 3, 2024

NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

February 28, 2024

NeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor Conference

February 11, 2024

NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity

January 31, 2024

NeuroBo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of DA-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

January 17, 2024

NeuroBo Pharmaceuticals Regains Compliance with Nasdaq Minimum Price Requirement

January 8, 2024

NeuroBo to Participate in Industry and Investor Conferences in January

January 1, 2024

Decks in 2024